RaySearch Laboratories ABRSLBF +13.37%90 Net Current Asset Value is $0.08 as of Mar. 2026, which is 100% below its 10-year median of 45.12. GuruFocus rates RSLBF with a GF Score™ of 90/100 and a GF Value™ of $20.91 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 275 Healthcare Providers & Services companies, RaySearch Laboratories AB ranks worse than 98.91% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
RaySearch Laboratories AB's net current asset value per share for the quarter that ended in Mar. 2026 was $0.08.
The historical rank and industry rank for RaySearch Laboratories AB's Net Current Asset Value or its related term are showing as below:
RSLBF'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 19.06 Med: 45.12 Max: 2074
Current: 400
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of RaySearch Laboratories AB was 2074.00. The lowest was 19.06. And the median was 45.12.
RSLBF's Price-to-Net-Current-Asset-Value is ranked worse than 98.91% of 275
companies
in the Healthcare Providers & Services industry
Industry Median: 6.05
vs RSLBF: 400.00
RaySearch Laboratories AB (OTCPK:RSLBF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
RaySearch Laboratories AB Net Current Asset Value Related Terms
RaySearch Laboratories AB Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for RaySearch Laboratories AB's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaySearch Laboratories AB Net Current Asset Value Chart
RSLBF vs VEEV, BTSG, TEM: Net Current Asset Value Comparison
For the Health Information Services subindustry, RaySearch Laboratories AB's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaySearch Laboratories AB Price-to-Net-Current-Asset-Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where RaySearch Laboratories AB's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.08 mean?
RaySearch Laboratories AB (RSLBF) has a Net Current Asset Value of $0.08 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on RaySearch Laboratories AB and its competitors. This is 100% below median its historical median of 45.12. Over the past decade, RaySearch Laboratories AB's Net Current Asset Value has ranged from 19.06 to 2,074.00. According to the industry distribution chart, RaySearch Laboratories AB ranks #272 out of 275 companies in the Healthcare Providers & Services industry, placing it in the top 98.9%.
Is RaySearch Laboratories AB's Net Current Asset Value too high?
RaySearch Laboratories AB's current Net Current Asset Value of $0.08 is 100% below median its 10-year median of 45.12. Over the past 10 years, this metric has ranged from a low of 19.06 to a high of 2,074.00. The Healthcare Providers & Services industry median Net Current Asset Value is 6.05. RaySearch Laboratories AB's value of $0.08 is 98.7% below this industry median. Based on the distribution chart, RaySearch Laboratories AB ranks #272 out of 275 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, RaySearch Laboratories AB has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's Net Current Asset Value compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, RaySearch Laboratories AB ranks #272 out of 275 companies for Net Current Asset Value. This places RaySearch Laboratories AB in the lower half of its industry. The industry median Net Current Asset Value is 6.05. RaySearch Laboratories AB's value of $0.08 is 98.7% below this benchmark. Historically, RaySearch Laboratories AB's own Net Current Asset Value has ranged from 19.06 to 2,074.00 over the past decade. While the company's 10-year median is 45.12 vs. the industry median of 6.05, RaySearch Laboratories AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Healthcare Providers & Services company?
The median Net Current Asset Value among Healthcare Providers & Services companies is 6.05, based on 275 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaySearch Laboratories AB's current Net Current Asset Value of $0.08 is 98.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on RaySearch Laboratories AB and its competitors. For the Healthcare Providers & Services industry, the median Net Current Asset Value is 6.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaySearch Laboratories AB's current Net Current Asset Value is $0.08, which is 100% below median its own 10-year median of 45.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (RSLBF) is currently considered Modestly Overvalued. The stock's GF Value™ is $20.91, compared to a current price of $24.00 — trading 14.8% above its estimated fair value. The current Net Current Asset Value is $0.08, which is 100% below median its 10-year median of 45.12 and 98.7% below the Healthcare Providers & Services industry median of 6.05. RaySearch Laboratories AB's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For RaySearch Laboratories AB (RSLBF), the current Net Current Asset Value is $0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaySearch Laboratories AB (RSLBF) Overvalued in 2026?
Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be overvalued.
The current stock price of $24.00 is trading 14.8% above its estimated GF Value™ of $20.91.
GuruFocus considers RaySearch Laboratories AB to be Modestly Overvalued.
Key valuation signals for RSLBF:
Net Current Asset Value: $0.08 (100% below median its 10-year median of 45.12)
GF Value™: $20.91 vs. price of $24.00 (14.8% above fair value)
Industry Position: 98.7% below the Healthcare Providers & Services median (#272 of 275)
No single metric tells the full story. See the RSLBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
90GF Score
Get the complete analysis for RSLBF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RSLBF has been successfully added to your 
